44 results about "Family Flaviviridae" patented technology

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from seine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (Sequence ID No. 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.

Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, L¹, V, W, T, Z, R, Y¹, and p are as defined herein.

The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.

Provided are compounds of Formula I:

and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

2-amino-pyrido(3,2-d)pyrimidine derivatives with a specific substitution pattern on positions 4 and 6 of the core structure are useful in the treatment or prevention of an infection due to a virus from the Flaviviridae family, especially HCV, when administered to a patient in a therapeutically effective amount.

Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R<2>, m, R, V, W, T, Z, R<1>, Y and p are disclosed herein.

The invention provides a vaccine for preventing duck egg reduction syndrome caused by BYD virus and a preparation method thereof. The invention provides a duck BYD virus (Family Flaviviridae, Genus Flavivirus, Ntaya virus group, Duck BYD virus) JXSP strain, and the preservation number is CGMCC No.5266. The virulent strain provided by the invention is duck BYD virus virulent strain with excellent immunogenicity. The virulent strain is vaccinated onto a sensitive cell to obtain cell sap, which is emulsified after being inactivated so as to obtain the safe, effective and controllable duck BYD virus inactivated vaccine, so that the prevention and the control of the duck egg reduction syndrome can be favored.

The invention is related to anti-viral compounds of formula (A) as defined in the claims, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well to processes and intermediates useful for preparing such compounds.

The invention belongs to the technical field of medicines, and relates to a phosphoramidate derivative of a nucleoside compound and application thereof, and a pharmaceutical composition containing thecompound. The phosphoramidate derivative can be used as an antiviral reagent, especially an anti-SARS-CoV-2 reagent. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preventing or treating viral infection, including but not limited to flaviviridae viral infection, filamentousvirology viral infection, enterovirus viral infection, orthomyxoviridae viral infection, paramyxoviridae viral infection and coronavirus viral infection, especially SARS-CoV-2 infection.

Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species.

Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R³, X, V, W, T, Z, R, Y¹, and p are as defined herein.

Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.

The invention provides a universal reverse transcription-recombinase-aided amplification-lateral flow dipstick (RT-RAA-LFD) amplification primer and testing method for dengue viruses. According to theuniversal RT-RAA-LFD amplification primer, a pair of specific primers used for an RAA technology is designed for untranslated regions being common conserved regions of 3' ends of dengue viruses types1-4, and a 5' end of a forward primer and a 5' end of a reverse primer are labeled with 6-carboxyfluorescein (FAM) and biotin respectively, thus making two ends of a positive double-chain amplification product labeled with the FAM and the biotin respectively; then, by utilizing a lateral flow dipstick coated with a colloidal gold labeled anti-FAM antibody and streptavidin, macroscopic interpretation is performed on an amplification result by an immuno-chromatography method, and dependence on a fluorescent quantitative instrument is rid; the minimum testing concentration is 10 copies/[mu]L, and the lateral flow dipstick has no cross reaction with other viruses of flaviviridae. By using the amplification primer and method for clinical specimens, the dengue virus RNA can be successfully tested, and the consistency of a testing result obtained by the method and a fluorescent quantitative polymerase chain reaction (PCR) testing result reaches 96%.